Individuals with clinically high-risk features who do not show variant in the classic genes should be tested for the rarer genes [15], while targeted germline variant testing of RET, neurofibromatosis type 1 (NF1) or von Hippel-Lindau syndrome (VHL) are considered for individuals with syndromic presentation. Here, VHL is linked to von Hippel-Lindau disease.